ISRCTN89337058
Completed
未知
Assessment of the immunogenicity and safety of the Northern Hemisphere 2010/2011-season influenza vaccine in elderly and young subjects according to European Medicines Agency (EMEA) regulations: an open label, non-randomised uncontrolled safety and efficacy study
Crucell Switzerland AG (Switzerland)0 sites110 target enrollmentJanuary 21, 2011
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Crucell Switzerland AG (Switzerland)
- Enrollment
- 110
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Healthy female and male volunteers equal to or older than 18 years of age on the day of enrolment
- •2\. Written informed consent
Exclusion Criteria
- •1\. Pregnancy and lactation
- •2\. Serious adverse reaction to any influenza vaccine
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Assessment of the immunogenicity and safety of the Northern Hemisphere 2009/2010-season influenza vaccine in elderly and young subjects according to European Medicines Agency (EMEA) regulationsISRCTN30202688Crucell, Berna Biotech Ltd (Switzerland)110
Completed
Not Applicable
Assessment of the immunogenicity and safety of the Northern Hemisphere 2009/2010-season influenza vaccine in children aged 6 to 35 months in comparison to a commercially available influenza vaccineInfluenzaRespiratoryInfluenza, virus not identifiedISRCTN10483274Berna Biotech Ltd, a Crucell Company (Switzerland)1,239
Completed
Not Applicable
Assessment of the immunogenicity and safety of the Northern Hemisphere 2008/2009-season influenza vaccine in elderly and young subjects according to European Medicines Agency (EMEA) regulationsISRCTN40098615Crucell, Berna Biotech Ltd (Switzerland)110
Completed
Phase 1
Reactogenicity and Immunogenicity of the pentavalent vaccine DPT-HB+Hib. Schedule 2-4-6 months.Prophylaxis against infections diseases: Diphtheria, Tetanus, B. pertussis, H. influenzae type b and hepatitis B.RPCEC00000103Center for Genetic Engineering and Biotechnology (CIGB).624
Not yet recruiting
Phase 1
ABDALA Clinical StudyCOVID-19SARS-CoV2Disease PreventionCoronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirusRPCEC00000346Center for Genetic Engineering and Biotechnology (CIGB), in Havana